AVANIR PHARMACEUTICALS AWARDED $2 MILLION NIH GRANT TO CONTINUE DEVELOPMENT OF HUMAN ANTIBODY TO ANTHRAX TOXIN

Avanir Pharmaceuticals today announced it has been awarded a $2 million grant from the National Institutes of Health/National Institute of Allergy and Infectious Disease (NIH/NIAID) under its Cooperative Research Partnerships for Biodefense program. The NIH/NIAID grant provides funds to establish a cGMP manufacturing process and to test efficacy of the fully human monoclonal antibody treatment against inhalation anthrax in non-human primates. Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=3031309)